Medindia

X

Florida and California Represent Equivalent Areas of Opportunity in the Alzheimer's Disease Drug Market

Tuesday, January 6, 2009 General News J E 4
Advertisement




Florida's Alzheimer's Disease Population is Undertreated When Compared to California, According to a New Analytics Tool From Decision Resources



WALTHAM, Mass., Jan. 6 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Florida and California represent equivalent areas of opportunity in the Alzheimer's disease drug market despite the large disparity in population size between the two states. Despite having a population half the size of California, Florida's more elderly-leaning population causes it to have almost the same number of Alzheimer's disease cases as the larger state (213,900 cases versus 263,900 cases, respectively).



"When we looked at other states such as New York and Texas, which have more residents than Florida, we found both to have fewer Alzheimer's patients because they have younger populations on average," stated Jason LaBonte, Ph.D., vice president of new product development at Decision Resources.



The new analytics tool entitled PatientFinder: Alzheimer's Disease estimates that, based on prescription volumes in both states, Florida's Alzheimer's population is undertreated versus California's, such that there are almost equal numbers of untreated Alzheimer's patients in each region (130,000 in California and 123,500 in Florida).



Why Pharmaceutical Companies Need this Information

With the type of information included in PatientFinder, pharmaceutical organizations can identify the local markets that offer the greatest opportunity for their branded drug. Companies can identify markets that are underserved and determine if they should increase direct-to-consumer advertising, work with the local managed care organizations to increase awareness of the disease and benefits of their drug or align sales representatives to maximize market potential.



About PatientFinder

PatientFinder is the only healthcare analytics tool that assesses local markets for expansion opportunity by determining the number of insured patients in each territory who have the disease but are untreated. PatientFinder covers each of the 50 U.S. states and 318 U.S. metropolitan statistical areas (MSAs) and provides:





About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.



About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.



All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.



-- Disease-specific prevalence numbers for each U.S. state and MSA -- Examination of treatment rates for the disease population to create percent treated and percent untreated estimates by state and MSA -- Unique analysis of the untreated population examined through a filter of prescription (Rx) benefit coverage. The end result is an estimate of how many patients are untreated but can afford therapy within each territory--the true local measure of opportunity for pharmaceutical companies

SOURCE Decision Resources
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Randy Jackson and the American Heart Association E...
S
Chimerix Completes Phase I Study and Initiates a P...